An observational study in Acute Respiratory Failure, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-09.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Severe SARS-CoV-2 infections are frequently associated with the acute respiratory distress syndrome (ARDS), which leads to a mortality of 30-40%. An altered type I interferon (IFN) response has been demonstrated in patients with severe COVID-19, together with a high viral load.
The aim of the current work is, in a large cohort of patients with severe COVID-19 admitted in the ICU, to determine the prevalence of patients with positive anti-IFN antibodies and to determine their outcome, as compared to patients having negative anti-IFN antibodies.
Severe SARS-CoV-2 infections are frequently associated with the acute respiratory distress syndrome (ARDS), which leads to a mortality of 30-40%. An altered type I interferon (IFN) response has been demonstrated in patients with severe COVID-19, together with a high viral load. A recent study revealed that 10% of patients admitted in the intensive care unit (ICU) for severe COVID-19 had positive type I anti-IFN antibodies. Such finding has potentially important therapeutic implications, as patients having positive anti-IFN antibodies could benefit from targeted interventions, including plasmapheresis. The aim of the current work is, in a large cohort of patients with severe COVID-19 admitted in the ICU, to determine the prevalence of patients with positive anti-IFN antibodies and to determine their outcome, as compared to patients having negative anti-IFN antibodies.
7,638 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 1,022 is above the median of 260 across 3,135 observational studies indexed under COVID-19.
Browse COVID-19 studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with proven SARS-CoV-2 infection and acute respiratory failure admitted in the intensive care unit
Exclusion Criteria:
day-28 mortality
comparaison of day-28 mortality in patients having positive versus negative type I anti-IFN antibodies
Time frame: at day-28 of intensive care unit (ICU) admission
rate of positivity of type I anti-IFN antibodies
positivity of type I anti-IFN antibodies measured on a serum sample obtained at any time during ICU stay
Time frame: 3 months of ICU admission
Factors associated with type I anti-IFN antibody positivity
Factors associated with type I anti-IFN antibody positivity available upon hospital admission, identified using uni- and multiple logistic regression analyses
Time frame: 24 hours of ICU admission
hospital mortality
Comparaison of hospital mortality of patients having positive versus negative type I anti-IFN antibodies
Time frame: at day 90.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris